A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
The purpose of this study is to learn about the effects of the study drug, when compared to NB-UVB (narrow-band ultraviolet B) phototherapy or placebo (an inactive substance that may resemble an active substance but has no medical value) injection on inflammation and heart disease risk factors.
Moderate to severe plaque psoriasis
18 years of age and older.
Moderate to severe plaque psoriasis.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Subjects will be in this study for 12 weeks. If randomized to the phototherapy group, there will be up to 40 visits. If randomized to the study drug group, there would be up to 11 visits.
Maureen Keene 503-228-7350
National Heart, Lung, and Blood Institute (NIH)
Depending on the group subjects enter and the number of visits they complete, they will be compensated a maximum of either $440 or $940. Subjects will be compensated $20 to offset travel and other indirect costs for participating. Visits in which subjects receive an FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography/computed tomography) scan will pay $110 per visit.